ada guidelines glp 1 Standards of Medical Care in Diabetes—2015 Abridged for Primary Care Providers 2026 Diabetes Treatment Guidelines Update:

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes

As mentioned by Lingvay et al., semaglutide has shown promise as a treatment option for non-diabetics with established atherosclerotic disease by reducing their risk of MACE by 20% despite having varying HBA1c baselines [47]

Getting the measure of the pressure: optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure

I think the direction of travel is the same, but there could be both an upside and a downside to our guidance depending on the pace of approval of generics in Canada. BMO does not expect the issue to spill over to the U.S